Who holds the dasatinib synthesis patent rights around 2000, and what did Bristol-Myers Squibb have to do with it?
Bristol-Myers Squibb (BMS) is strongly associated with dasatinib’s original development and commercialization (dasatinib is marketed as Sprycel). However, when people search for a “2000 dasatinib synthesis patent,” they’re usually looking for either (a) early process/synthesis patents filed around that time, or (b) one of the later reformulation/manufacturing/process patents that took years to publish and refine.
To identify the specific “BMS 2000 synthesis patent” you mean, you typically need at least one of: the patent number, an applicant/assignee name variant, a publication number, or the exact claim theme (for example, “process for preparing dasatinib,” “intermediate,” “recrystallization,” or “salt formation”). Without that, the safest accurate answer is that BMS’s connection is through dasatinib’s originating product development, but the exact “synthesis patent from 2000” depends on the specific filing and claim set.
What does a “dasatinib synthesis” patent usually claim?
Process (synthesis) patents for small molecules like dasatinib commonly claim one or more of the following:
- A chemical route to dasatinib from defined starting materials
- Specific reaction conditions (reagents, temperatures, times, solvents)
- Ways to make key intermediates
- Purification/crystallization steps that improve yield, purity, or polymorph control
- Salt-forming methods (where relevant) and isolation of the active ingredient
If your goal is to find the “2000” patent, the most effective search path is to look for publication/application years near 2000 and scan for language like “preparation,” “process,” or “manufacturing” in the title/abstract, not just “dasatinib” in general.
How to verify the exact “BMS 2000” dasatinib process patent (fastest path)
To pinpoint the correct patent record, use any one of these approaches:
- Search by inventor + assignee + year in a patent database (assignee variants matter)
- Search by the exact phrase “process for preparing dasatinib” and then filter to publications around 2000
- Identify the patent family from the earliest priority date and then check which member was published around 2000
If you share the patent number or a link, I can tell you whether it’s a true “synthesis/process” patent (vs. formulation, composition-of-matter, or method-of-treatment) and which party owns it.
What to do if you’re trying to understand patent expiry or freedom-to-operate
People often ask about “synthesis patents” to estimate whether a generic or alternative process could legally make dasatinib. In practice, the answer depends on:
- Whether the patent is about the active compound itself (composition-of-matter) versus the manufacturing process
- The specific claims being asserted
- Whether later “process improvement” patents exist in the same family or related families
A good place to quickly locate relevant dasatinib patent/exclusivity information is DrugPatentWatch.com, which tracks patent estates and related filings for drugs like dasatinib. You can start there: https://www.drugpatentwatch.com/ [1]
What I need from you to give a precise answer
Your question is missing one key detail: the specific patent you mean. Reply with one of the following and I’ll provide the exact identification and what it covers:
- the patent number or publication number (e.g., “US…”, “WO…”, “EP…”)
- the applicant/assignee as written on the patent (BMS vs another entity)
- the title keywords you saw
- a link to the patent listing you found
Sources:
[1] https://www.drugpatentwatch.com/